| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
1 company
Joel Lewis is President and CEO at GALT. Joel Lewis's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.8M at current prices.
Historically, Joel Lewis's trades have earned a middling insider score of 67/100 across 14 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of -14.5%.
The GALT filings lean toward selling, a net 197,412 shares.
Joel Lewis has 108 Form 4 filings on record from January 2019 to January 2026, all as President and CEO at Galectin Therapeutics (GALT), 2019–2026.
The 129 reported transactions were 86 stock awards, 13 option or other derivative awards, 12 open-market sales and 11 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $17K and 8 sales worth about $759K.
The largest open-market purchase was 1,000 shares of GALT at an average $4.80 on January 29, 2019, about $5K.
The largest open-market sale was 84,000 shares of GALT at an average $3.82 on January 6, 2026, about $321K.
All 8 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 84,000 | $3.82 | $321,134.30 | -9.2% | -25.8% | - | |
| Dec 17, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 7,829 | $7.06 | $55,241.42 | -0.9% | -51.3% | - | |
| Nov 18, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 22,463 | $6.07 | $136,365.82 | -2.6% | -55.7% | - | |
| Nov 10, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 1,867 | $6.03 | $11,252.22 | -0.2% | -47.7% | - | |
| Nov 5, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 200 | $6.00 | $1,200.00 | - | -42.3% | - | |
| Nov 4, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 15,720 | $6.07 | $95,342.40 | -1.9% | -47.1% | - | |
| Sep 12, 2025 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 14,000 | $6.36 | $89,048.40 | -1.7% | +6.3% | -27.2% | |
| Dec 23, 2024 | GALT Galectin Therapeutics Inc | President and CEO | Sale+OE10b5-1 | 56,000 | $0.89 | $49,610.40 | -5.9% | +85.4% | +348.3% | |
| Apr 24, 2024 | GALT Galectin Therapeutics Inc | President and CEO | Buy | 1,000 | $3.39 | $3,390.00 | +100.0% | -21.3% | -56.8% | |
| Feb 16, 2023 | GALT Galectin Therapeutics Inc | President and CEO | Buy | 1,000 | $1.52 | $1,520.00 | New | +11.3% | +16.0% |